Stellar Biotch Cm ST (SBOT) 2.48 $SBOT Stellar
Post# of 273323
Posted On: 09/24/2016 5:03:11 PM
Stellar Biotch Cm ST (SBOT) 2.48 $SBOT
Stellar Biotechnologies to Present at International Aquaculture Symposium
Marketwire Canada - Wed Sep 21, 7:30AM CDT
PORT HUENEME, CA--(Marketwired - Sep 21, 2016) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(NASDAQ: SBOT), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), will present at the VIII Simposio Internacional de Sanidad e Inocuidad Acuícola (VIII International Symposium on Aquaculture Health and Safety) in Ensenada, Baja California, Mexico, September 22-23, 2016.
SBOT: 2.48 (-0.06)
Stellar Biotechnologies to Present at the 18th Rodman & Renshaw 2016 Annual Global Investment Conference
Marketwired - Tue Sep 06, 7:30AM CDT
PORT HUENEME, CA--(Marketwired - Sep 6, 2016) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (NASDAQ: SBOT), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH", today announced that the Company will present at the Rodman & Renshaw 18th Annual Global Investment conference being held September 11-13, 2016 at the Lotte New York Palace Hotel in New York, NY.
SBOT: 2.48 (-0.06)
Stellar Biotechnologies Reports Third Quarter 2016 Financial Results and Operational Highlights
Marketwire Canada - Tue Aug 09, 7:00AM CDT
PORT HUENEME, CA--(Marketwired - Aug 9, 2016) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (NASDAQ: SBOT), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), announces its financial results for its third fiscal quarter and nine months ended June 30, 2016.
SBOT: 2.48 (-0.06)
Stellar Biotechnologies Announces Third Quarter 2016 Corporate Update Conference Call
Marketwired - Thu Aug 04, 7:30AM CDT
PORT HUENEME, CA--(Marketwired - Aug 4, 2016) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (NASDAQ: SBOT), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH", will host its third quarter 2016 corporate update conference call and live webcast on Wednesday, August 10, at 1:30pm ET / 10:30am PT.
SBOT: 2.48 (-0.06)
Stellar Biotechnologies to Present at LD Micro Invitational Conference
Marketwire Canada - Thu Jun 02, 7:00AM CDT
PORT HUENEME, CA--(Marketwired - Jun 2, 2016) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (NASDAQ: SBOT), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH", today announced that the Company will present at the LD Micro Invitational Conference, to be held June 7-9, 2016 at the Luxe Sunset Bel Air Hotel in Los Angeles, CA.
SBOT: 2.48 (-0.06)
Stellar Biotechnologies Named as a 2016 California Small Business of the Year
Marketwired - Wed May 25, 8:02AM CDT
PORT HUENEME, CA--(Marketwired - May 25, 2016) - Stellar Biotechnologies, Inc. ("Stellar" or "Company" (NASDAQ: SBOT), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH", announced that the Company will be recognized as a 2016 California Small Business of the Year in ceremonies today at the state capitol in Sacramento, California.
SBOT: 2.48 (-0.06)
Stellar Biotechnologies Appoints Michael L. Klein, Ph.D. as Vice President of Chemistry, Manufacturing and Controls (CMC)
Marketwired - Mon May 23, 7:30AM CDT
PORT HUENEME, CA--(Marketwired - May 23, 2016) - Stellar Biotechnologies, Inc. ("Stellar" or "Company" (NASDAQ: SBOT), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH", today announced the appointment of Michael L. Klein, Ph.D. as Vice President of Chemistry, Manufacturing and Controls ("CMC". Dr. Klein will assume management responsibility for the Company's pharmaceutical manufacturing and product development functions and serve as the Company's representative on all activities related to CMC.
SBOT: 2.48 (-0.06)
Neovacs and Stellar Biotechnologies sign joint venture agreement to create Neostell SAS
GlobeNewswire - Thu May 12, 1:15AM CDT
Neovacs (Alternext Paris:ALNEV) a leader in active immunotherapy for the treatment of autoimmune diseases, today announced that the Company has finalized the terms of its partnership with US company Stellar Biotechnologies Inc. ("Stellar" (Nasdaq:SBOT), to determine the creation of the production company Neostell SAS under a form of a joint venture, based in the Paris area and owned 70% by Neovacs and 30% by Stellar Biotechnologies.
SBOT: 2.48 (-0.06)
Stellar Biotechnologies and Neovacs Sign Joint Venture Agreement to Manufacture Conjugated Therapeutic Vaccines With Stellar KLH(TM)
Marketwire Canada - Wed May 11, 9:04AM CDT
PORT HUENEME, CA and PARIS, FRANCE and BOSTON, MA--(Marketwired - May 11, 2016) - Stellar Biotechnologies, Inc. ("Stellar" (NASDAQ: SBOT) and Neovacs S.A. ("Neovacs" (Alternext Paris: ALNEV) today announced their entry into a joint venture agreement to manufacture and sell conjugated therapeutic vaccines (the "Joint Venture" using Stellar's proprietary Keyhole Limpet Hemocyanin (KLH).
SBOT: 2.48 (-0.06)
Stellar Biotechnologies Reports Second Quarter 2016 Financial Results and Operational Highlights
Marketwire Canada - Mon May 09, 4:19PM CDT
PORT HUENEME, CA--(Marketwired - May 9, 2016) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (NASDAQ: SBOT), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH", announces its financial results for its second fiscal quarter ended March 31, 2016.
SBOT: 2.48 (-0.06)
Stellar Biotechnologies Announces Second Quarter 2016 Corporate Update Conference Call
Marketwired - Tue May 03, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (NASDAQ: SBOT), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH", will host its second quarter 2016 corporate update conference call and live webcast on Wednesday, May 11 at 1:30pm ET / 10:30am PT.
SBOT: 2.48 (-0.06)
Stellar Biotechnologies to Present at International Aquaculture Symposium
Marketwire Canada - Wed Sep 21, 7:30AM CDT
PORT HUENEME, CA--(Marketwired - Sep 21, 2016) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(NASDAQ: SBOT), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), will present at the VIII Simposio Internacional de Sanidad e Inocuidad Acuícola (VIII International Symposium on Aquaculture Health and Safety) in Ensenada, Baja California, Mexico, September 22-23, 2016. SBOT: 2.48 (-0.06)
Stellar Biotechnologies to Present at the 18th Rodman & Renshaw 2016 Annual Global Investment Conference
Marketwired - Tue Sep 06, 7:30AM CDT
PORT HUENEME, CA--(Marketwired - Sep 6, 2016) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(NASDAQ: SBOT), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH", today announced that the Company will present at the Rodman & Renshaw 18th Annual Global Investment conference being held September 11-13, 2016 at the Lotte New York Palace Hotel in New York, NY. SBOT: 2.48 (-0.06)
Stellar Biotechnologies Reports Third Quarter 2016 Financial Results and Operational Highlights
Marketwire Canada - Tue Aug 09, 7:00AM CDT
PORT HUENEME, CA--(Marketwired - Aug 9, 2016) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(NASDAQ: SBOT), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), announces its financial results for its third fiscal quarter and nine months ended June 30, 2016. SBOT: 2.48 (-0.06)
Stellar Biotechnologies Announces Third Quarter 2016 Corporate Update Conference Call
Marketwired - Thu Aug 04, 7:30AM CDT
PORT HUENEME, CA--(Marketwired - Aug 4, 2016) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(NASDAQ: SBOT), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH", will host its third quarter 2016 corporate update conference call and live webcast on Wednesday, August 10, at 1:30pm ET / 10:30am PT. SBOT: 2.48 (-0.06)
Stellar Biotechnologies to Present at LD Micro Invitational Conference
Marketwire Canada - Thu Jun 02, 7:00AM CDT
PORT HUENEME, CA--(Marketwired - Jun 2, 2016) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(NASDAQ: SBOT), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH", today announced that the Company will present at the LD Micro Invitational Conference, to be held June 7-9, 2016 at the Luxe Sunset Bel Air Hotel in Los Angeles, CA. SBOT: 2.48 (-0.06)
Stellar Biotechnologies Named as a 2016 California Small Business of the Year
Marketwired - Wed May 25, 8:02AM CDT
PORT HUENEME, CA--(Marketwired - May 25, 2016) - Stellar Biotechnologies, Inc. ("Stellar" or "Company"
(NASDAQ: SBOT), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH", announced that the Company will be recognized as a 2016 California Small Business of the Year in ceremonies today at the state capitol in Sacramento, California. SBOT: 2.48 (-0.06)
Stellar Biotechnologies Appoints Michael L. Klein, Ph.D. as Vice President of Chemistry, Manufacturing and Controls (CMC)
Marketwired - Mon May 23, 7:30AM CDT
PORT HUENEME, CA--(Marketwired - May 23, 2016) - Stellar Biotechnologies, Inc. ("Stellar" or "Company"
(NASDAQ: SBOT), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH", today announced the appointment of Michael L. Klein, Ph.D. as Vice President of Chemistry, Manufacturing and Controls ("CMC". Dr. Klein will assume management responsibility for the Company's pharmaceutical manufacturing and product development functions and serve as the Company's representative on all activities related to CMC. SBOT: 2.48 (-0.06)
Neovacs and Stellar Biotechnologies sign joint venture agreement to create Neostell SAS
GlobeNewswire - Thu May 12, 1:15AM CDT
Neovacs (Alternext Paris:ALNEV) a leader in active immunotherapy for the treatment of autoimmune diseases, today announced that the Company has finalized the terms of its partnership with US company Stellar Biotechnologies Inc. ("Stellar"
(Nasdaq:SBOT), to determine the creation of the production company Neostell SAS under a form of a joint venture, based in the Paris area and owned 70% by Neovacs and 30% by Stellar Biotechnologies. SBOT: 2.48 (-0.06)
Stellar Biotechnologies and Neovacs Sign Joint Venture Agreement to Manufacture Conjugated Therapeutic Vaccines With Stellar KLH(TM)
Marketwire Canada - Wed May 11, 9:04AM CDT
PORT HUENEME, CA and PARIS, FRANCE and BOSTON, MA--(Marketwired - May 11, 2016) - Stellar Biotechnologies, Inc. ("Stellar"
(NASDAQ: SBOT) and Neovacs S.A. ("Neovacs" (Alternext Paris: ALNEV) today announced their entry into a joint venture agreement to manufacture and sell conjugated therapeutic vaccines (the "Joint Venture" using Stellar's proprietary Keyhole Limpet Hemocyanin (KLH). SBOT: 2.48 (-0.06)
Stellar Biotechnologies Reports Second Quarter 2016 Financial Results and Operational Highlights
Marketwire Canada - Mon May 09, 4:19PM CDT
PORT HUENEME, CA--(Marketwired - May 9, 2016) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(NASDAQ: SBOT), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH", announces its financial results for its second fiscal quarter ended March 31, 2016. SBOT: 2.48 (-0.06)
Stellar Biotechnologies Announces Second Quarter 2016 Corporate Update Conference Call
Marketwired - Tue May 03, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(NASDAQ: SBOT), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH", will host its second quarter 2016 corporate update conference call and live webcast on Wednesday, May 11 at 1:30pm ET / 10:30am PT. SBOT: 2.48 (-0.06)
(0)
(0)